描述初级中枢神经系统淋巴瘤的第二线和超越治疗方法
Brian Primeaux1, Chelsea Luo1, Erin K Yeung1
1The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hematological oncology
|September 28, 2024
概括
复发性或耐药性初级中枢神经系统淋巴瘤 (PCNSL) 的治疗方法各不相同. 这项研究描述了现实世界的疗法,发现了多样化的二线和超越治疗方法. 需要进行进一步的临床试验,以确定R/R PCNSL的最佳管理.
科学领域:
- 神经瘤学神经瘤学
- 血液学 血液学 血液学
- 临床药房 临床药房
背景情况:
- 主要中枢神经系统淋巴瘤 (PCNSL) 是一种罕见的,激进的脑癌.
- 基于高剂量甲状腺醇 (HDMTX) 的疗法是标准的前线治疗.
- 在多达一半的PCNSL患者中发生复发,对于复发/耐药 (R/R) 疾病没有确定的首选治疗方法.
研究的目的:
- 描述用于复发性或耐火性 (R/R) PCNSL的现实世界治疗方法.
- 描述PCNSL前线治疗后的整合策略.
主要方法:
- 54名成年PCNSL患者的回顾性描述性分析,这些患者接受HDMTX前线治疗.
- 收集了关于前线整合和R/R疾病后续治疗线的数据.
- 排除标准包括二级中枢神经系统淋巴瘤,非B细胞PCNSL和眼内淋巴瘤.
主要成果:
- 31名患者 (57%) 接受了整合 (R-HDAC,WBRT或两者兼而有之);13名 (24%) 接受了自动SCT.
- 25名患者进展,其中17人接受了二线治疗,包括WBRT,临床试验,R2,HDMTX再诱导,ibrutinib或R-HDAC.
- 随后的治疗线路显示出基于患者和医生因素的显著治疗方案变化.
结论:
- 对于R/R PCNSL的现实世界治疗是高度可变和个性化的.
- 前线治疗后的巩固策略也显示出多样性.
- 未来的临床试验对于确定R/R PCNSL的最佳治疗方法至关重要.
更多相关视频
相关概念视频
01:27Tumor Immunotherapy
489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K